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increased 161.8%, and any oxycodone-containing compound
increased 267.3%. Mentions of each of these three classes of
opioids remained less than 2% of all total drug mentions per
year for each year studied. Medical use of the selected opioid
classes, as reported in the ARCOS database and measured by
grams distributed, all increased substantially (fentanyl 151.2%,
morphine 48.8%, oxycodone 347.9%). CONCLUSIONS: Using
this method of analysis, the rates of drug abuse, and resultant
morbidity secondary to the use of opioid analgesics, remains low
in spite of the increase in medical use of these substances.
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Secondary analysis of the Medical Expenditure Panel Survey
(MEPS) from 1996 to 1999. OBJECTIVE: To examine patterns
in opioid use in 1996, 1997, 1998 and 1999 among individuals
with back pain in the US, and to investigate trends in the use of
overall and individual opioid category. No study has examined
at a national level the patterns and trends of opioid use among
individuals with back pain. METHODS: Individuals with back
pain were stratiﬁed by socio-demographic characteristics and
geographical regions. Rates of overall opioid use were compared
among different strata. To investigate trends in opioid use, use
rates of the overall and individual opioid category were calcu-
lated and compared. From 1996 to 1999, the use of opioid was
not signiﬁcantly different across different gender or racial/ethni-
cal groups, but signiﬁcantly higher among individuals who were
publicly insured, had low or below low income and had educa-
tion at or below 12th grade compared to their respective coun-
terparts. During the 4-year period, signiﬁcant variations in
opioid use across different age groups or geographic regions 
were observed in early years. But the variations became non-
signiﬁcant in later years. RESULTS: Trend analysis indicated that
the rates of overall opioid use increased slightly across the 4-year
span. Among individual opioid categories, the use of oxycodone
or hydrocodone increased whereas the use of propoxyphene
decreased. CONCLUSIONS: The signiﬁcantly higher use of
opioids among individuals who were publicly insured, had low
or below low income and had education at or below 12th grade
raised serious concerns about drug safety in this patient popula-
tion. The increase in the use of hydrocodone and oxycodone
indicated a need to better assess the efﬁcacy and safety associ-
ated with these drugs among individuals with back pain.
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Secondary analysis of the 2000 Medical Expenditure Panel
Survey (MEPS). OBJECTIVE: To examine national prescription
patterns of non-steroidal anti-inﬂammatory drugs (NSAIDs) and
muscle relaxants among individuals with back pain in the United
States. Summary of Background Data. There is a lack of infor-
mation on national prescription patterns of NSAIDs and muscle
relaxants among individuals with back pain in the US.
METHODS: Traditional NSAIDs, cyclooxygenase-2-speciﬁc
(COX-2) inhibitors and muscle relaxants were investigated. Indi-
viduals with back pain were stratiﬁed by socio-demographic
characteristics and geographical regions. For each medication
category, overall prescribing frequency was compared across dif-
ferent strata and individual drug prescription was analyzed.
RESULTS: Traditional NSAIDs, COX-2 inhibitors and muscle
relaxants respectively accounted for 16.3%, 10% and 18.5% of
total prescriptions for back pain in 2000. Among individual
drugs, ibuprofen and naproxen accounted for most of the pre-
scriptions for traditional NSAIDs (60%), whereas two-thirds 
of the prescriptions for muscle relaxants were attributable to
cyclobenzaprine, carisoprodol and methocarbamol. Prescription
of COX-2 inhibitors or muscle relaxants demonstrated wide
variations across different regions. Several individual character-
istics including age, race and educational level were associated
with the prescription of some of the medications. CONCLU-
SIONS: Neither traditional NSAIDs, nor COX-2 inhibitors, 
nor muscle relaxants dominated prescriptions for back pain.
However, a small number of individual drugs were attributable
to most of the prescriptions for traditional NSAIDs or muscle
relaxants. The prescription of some of the medications demon-
strated wide variations across different regions or different racial
and educational groups. More studies are needed to understand
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OBJECTIVES: To illustrate how use of generalized linear models
to analyze health care cost data may provide a better distribu-
tional ﬁt than commonly employed approaches (e.g., linear or
log-linear ordinary least squares [OLS] regression), and could
yield quantitatively and inferentially different conclusions.
METHODS: Data were obtained from the PharMetrics Patient-
Centric Database, which includes integrated medical pharmacy
claims from 73 health plans nationwide. Patients with a diag-
nosis of intermittent claudication (ICD-9-CM 443.9x) who
newly started cilostazol or pentoxifylline therapy between June
1999–March 2002 were selected for analysis. Six-month pre-
treatment and follow-up periods were created in relation to the
ﬁrst observed prescription. Total costs of care during follow-up
were estimated based on health plan payments for medications
and services rendered, and were expressed in 2002 U.S. dollars.
Alternative multivariate approaches to analyzing total costs were
employed–an OLS model (log-linear) versus a generalized linear
model (GLM) with a log-link function and a gamma distribu-
tion. Covariates included demographic and other baseline/
pretreatment variables. Histograms of untransformed and log-
transformed costs were compared to gamma and normal distri-
butions; goodness-of-ﬁt assessments also were conducted. The
results of OLS (on a log-transformed outcome) and gamma GLM
models were compared. RESULTS: Analyses were conducted for
763 and 506 patients newly starting cilostazol and pentoxifylline
therapy respectively. The results of goodness-of-ﬁt testing
(deviance: 1489.5 vs. 1366.4 for degrees of freedom = 1,255)
indicated that the gamma GLM model approximated the cost
distribution most closely. Observed annual mean total costs were
$6238 and $5568 for cilostazol and pentoxifylline respectively;
application of the two models yielded different results—a non-
signﬁcant (p = 0.0620) treatment effect using log-linear OLS, and
